• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ECDC publishes influenza virus characterisation

tetano

Editor, Senior Moderator
ECDC published a technical document on 'Influenza virus characterisation, Summary Europe, May?June 2011'. Over 450 virus specimens (propagated virus isolates or clinical samples) collected from January to May 2011 have been received from EU and EU-affiliated countries.

In particular, Influenza A(H1N1)pdm, influenza A(H3N2), and influenza B/Victoria/2/87 lineage viruses have been characterised genetically and antigenically. Some of the findings are:

Recently isolated A(H1N1)pdm viruses continue to fall into several genetic groups but all groups show
antigenic similarity to the currently recommended vaccine virus A/California/7/2009.
A(H3N2) viruses also continue to fall into distinct genetic groups with some viruses showing antigenic
difference from the currently used vaccine virus A/Perth/16/2009, but there is no consistent correlation of
altered antigenicity with any genetic group.
Influenza B viruses of the B/Victoria/2/87 lineage have predominated over those of the B/Yamagata/2/87
lineage. Most of the B/Victoria/2/87 lineage viruses are genetically and antigenically similar to the currently
recommended vaccine virus B/Brisbane/60/2008.

http://ecdc.europa.eu/en/publications/Publications/1106_Influenza_virus_characterisation.pdf
 
Back
Top